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Treatment of brain cancers, especially high grade gliomas (WHO stage III and IV) is slowly making progress, but not as fast as
medical researchers and the patients would like. Immunotherapy oﬀers the opportunity to allow the patient’s own immune system
a chance to help eliminate the cancer. Immunotherapy’s strength is that it eﬃciently treats relatively small tumors in experimental
animal models. For some patients, immunotherapy has worked for them while not showing long-term toxicity. In this paper, we
will trace the history of immunotherapy for brain cancers. We will also highlight some of the possible directions that this ﬁeld may
be taking in the immediate future for improving this therapeutic option.
1.Introduction
Immunotherapy for cancer has made progress and is now
becoming part of the treatment options that are more
frequently discussed with oncology patients. Previously, this
type of treatment was given to patients with advanced dis-
ease, with only a few months to live. Needless to say, the ﬁnal
results were often disappointing. While the failures told us
what strategies did not work, it showed that immunotherapy
was generally safe and did not immediately kill the patient.
It also showed that the dreaded autoimmunity was not
being induced. These results also spurred the development
ofdiﬀerentapproaches,afterbetterunderstandings of cancer
immunology were unexpectedly discovered. This illustrates
our need to learn more about basic in vivo cancer immunol-
ogy before clinical therapies can be fully predicted. The
proper timing and use of the right antibodies or cells has
also allowed this progress to occur. The herceptin antibody
targeting the her2/neu proto-oncogene has beneﬁted those
women with breast and ovarian cancers that overexpressed
this receptor. This discovery showed that targeting a cell-
surface receptor controlling a key biological function, as
opposed to any available tumor surface antigen, was the key
togeneratingusefulclinicalresponses.Recently,PROVENGE
marketed by Denderon Corp, was given FDA approval
in the USA to treat refractory prostate cancer in men.
This prostate tumor-antigen (prostatic acid phosphatase)-
granulocyte macrophage-colony stimulating factor fusion
protein does stimulate dendritic cells in vitro. When these ex
vivo activated dendritic cells are reintroduced back into the
patient, the host’s antitumor T cells are restimulated, which
subsequently attacks the cancer. This immune response does
translate into an additional four months of life. These two
success stories demonstrate that progress towards cancer is
slowly advancing and we eagerly await more successes as the
overall ﬁeld continues to advance and mature.
Glioblastoma multiforme (GBM, WHO stage IV) and
anaplastic astrocytomas (WHO stage III) are aggressive
and lethal cancers. These cancers are almost always fatal
within ﬁve years (2010 Central Brain Tumor Registry). These2 Clinical and Developmental Immunology
tumors are very invasive; this contributes to their resistance
to be cured by traditional surgical resection and directed
radiation therapy. Hencethe need to develop better therapies
still exists. The advantage of generating an immune response
towards a cancer is that the immune eﬀectors (cells or
antibodies) can now seek out and destroy the tumor cells
that are located in inaccessible sites that traditional surgery,
radiation, or chemotherapeutic drugs cannot reach.
Due to the relative isolation from the systemic circula-
tion, because of the blood brain barrier, the initiation of pro-
ductive immune responses in the brain is more limited than
other types of cancers [1]. Local microglial cells can process
and present tumor-associated antigens to T lymphocytes [2–
5]. However few na¨ ıve T cells normally transit into the brain.
Normal brain cells also express Fas Ligand and express TGF-
β [6, 7], making immune responses harder to be sustained.
Hence lymphoid cells must be recruited from the periphery
by a variety of cytokines and chemokines. Once eﬀector
lymphocytes inﬁltrate the tumor, they can mediate antibrain
tumor immunity. Despite these obstacles, progress is slowly
being made in neuro-onco-immunotherapy. Unless some
extraordinary discovery is made, immune-based therapies
must be combined with other modalities that target other
critical aspectsof cancerbiology. This paper willfocus on the
natural progressions that are leading us towards successful
immunotherapy for brain cancers.
2. Types of Immunotherapy
Immunological-based treatments have been used in several
ways to treat cancer. These include (1) nonspeciﬁc methods
using adjuvants, lymphokine activated killer cells, or gene-
modiﬁed tumor cells; (2) speciﬁc immunotherapy include
using monoclonal antibodies, tumor inﬁltrating lympho-
cytes, allogeneic reactive T cells, chimeric antigen-redirected
T cells, puriﬁed and cloned tumor antigens used either
alone or in combination with in vitro cultured dendritic cells
(DCs).
2.1. Nonspeciﬁc Approaches
2.1.1. Adjuvants. Nonspeciﬁc approaches include using nat-
ural adjuvants such as bacillus Calmette-Gu´ erin (BCG,
Mycobacteria bovis), muramyl dipeptide (MDP), Detox
(lipopolysaccharide with lipid A removed). Janeway [8]o n c e
wrote: “adjuvants are the immunologist’s dirty little secret,”
in that these molecules are needed to provoke the immune
response. Adjuvants work by stimulating local antigen pre-
senting cells such as dendritic cells, macrophages, and B
cells via toll-like receptors and pathogen-associated recog-
nition molecules. TLR receptor stimulants as imiquimod,
polyinosinic-polycytidylicacidstabilizedwithpolylysineand
carboxymethyl-cellulose (Poly ICLC), CpG containing DNA,
and other synthetic molecules are used to stimulate dendritic
cells, which activate either cell-mediated or humoral immu-
nity provided the antigens of choice are also present.
In some parts of the world, BCG is used as a prophylactic
vaccine to stimulate immunity towards Mycobacteria tuber-
culosis, due to its very strong immunogenic properties, as
well as common antigenic determinants. A puriﬁed protein
derived (PPD) from M. tuberculosis is the diﬀerence between
Freund’s complete and incomplete adjuvant commonly used
in antibody production in animals. BCG is also used in a
therapeutic vaccination setting to actively treat human blad-
der cancer [9]. Here the initial nonspeciﬁc inﬂammation in
response to BCG injected directly into the tumor leads to an
innate immune response that causes tumor cell death. After
the tumor dies it is followed by lasting cellular immunity
towards the bladder cancer. Wikstrand and Bigner [10] used
BCG and human glioma cells to generate good antibody
responses towards the glioma cells without any signs of
autoimmunity. Albright et al. [11]u s e dB C Gt ot r e a tG B M
patients in 1976. Here 107 BCG organisms were used as an
intradermal stimulus to induce delayed type hypersensitivity
(DTH) reactions. Their patients were subsequently injected
with autologous glioma cells with the puriﬁed protein
derivative (PPD). The theory here was that when the host
mounted the recall response towards the PPD, the glioma
antigens would be incorporated in this DTH response and
mount a primary immune response towards the glioma cells.
Once these antibodies and immunized lymphocytes were
elicited, they would then home into the brain tumors and
mediate their antitumor eﬀects. Unfortunately, this therapy
failed to achieve much inﬂammation within the relapsing
glioma along with no improved patient survival. The use of
adjuvantswaslargelyabandoned, until itsability tostimulate
dendritic cell maturation via diﬀerent receptors was recently
discovered (see dendritic cells).
2.1.2. Natural Adjuvants: Heat Shock Proteins (HSP). Heat
shock proteins are induced by a variety of stressful con-
ditions: heat, radiation, chemotherapy, nutrient starvation,
hypoxia, and so forth. These molecules are responsible
for assisting in the synthesis and correct folding of newly
synthesized proteins, thereby replacing the stress-damaged
proteins.
The HSPs were described as “natural adjuvants,” since
they provoke immunity [12]. Several of these HSPs: HSP70
and gp96 (also known as GRP94) were identiﬁed as tumor-
speciﬁc antigens [13]. In other cases, HSP70, HSP90, and
gp96 increased the immunogenicity of tumors by improving
T-cells immune responses [14, 15]. Proteins synthesized by
tumor cells include potential antigens. As these antigens
are degraded by the proteasome, it was reported that HSPs
acted as chaperones [14, 15]; these molecular chaperones
then shuttle these antigenic peptides to the endoplasmic
reticulum, where they can be eventually loaded onto the
MHC. Tumor cells can present HSPs on their surfaces
(our unpublished data), release these peptide/HSP com-
plexes, presumably via exosomes [16–18]. Here the host’s
antigen presenting cells (APCs), both dendritic cells and
macrophages, can take up these antigens/HSPs via the CD91
receptor [19]. Peptides complexed to HSPs stimulate better
immune responses than when the antigenic peptide is not
complexed to the HSP [13]. HSP70 and gp96 also have
been reported to enhance dendritic cell maturation [20, 21].
HSP70 also acts as a cytokine, which stimulates tumorClinical and Developmental Immunology 3
necrosis factor, IL-1 and IL-6 production from CD14+
monocytes [22]. These CD14+ cells also include the imma-
ture dendritic cells. Thus, HSPs might be able to stimulate
immune responses via its natural adjuvant activity, while
simultaneously delivering the antigenic peptides provoking
speciﬁc immune responses.
On the clinical level, Antigenics, Inc. (Lexington, MA)
has developed the technology to produce a clinical product
calledOncophage.Herethesurgicallyresectedtumoristaken
and the gp96 component (HSPPC-96) from the tumor is
isolated. This puriﬁed gp96 (presumably binding antigenic
peptides) is then formulated as a custom-made vaccine using
the GS-21 adjuvant for each patient. This approach has been
givenfasttrackandorphandrugdesignationsbytheUSFDA
and the EMEA for a couple of cancers. At the University of
California, San Francisco, Oncophage is being used in Phase
2 trials to treat GBM. At the recent International Conference
on Brain Tumor in Travemunde, Germany (May 2010), it
was reported that of the 32 evaluable patients with recurrent
GBM given Oncophage, 41% survived up to a year or longer
[23]. The authors also saw a robust immune response within
increasedTh1cytokineproductionbytheimmunizedTcells.
2.1.3. Lymphokine Activated Killer Cells (LAK). LAK cells are
NK and NK-T like (CD8+) cells that when stimulated with
lymphokines (cytokines) like interleukin-2 (IL-2) become
nonspeciﬁc tumoricidal cells. LAK cells kill most, if not all,
tumor cells quite well in vitro in a non-MHC restricted
manner. When IL-2 or interferon-γ (IFN-γ)t r a n s d u c e d
ﬁbroblasts were coinjected with the murine GL261 glioma,
the glioma cells were rejected by the recruited NK and LAK
cells. The LAK cells were activated in situ by the cytokines
[24].HoweverinaratgliomamodelusingtheF98gliomacell
line, the recruited rat LAK cells were not as successful as the
previous mouse model [25]. The clinical application of LAK
cells has been eﬀective only towards some melanoma and
renal cancers [26]. Occasionally a response towards a human
glioma is seen [27, 28]. Hoag Hospital in Newport Beach
(California) is currently using LAK cells that are implanted
into their patient’s brain tumor cavity after surgery [29, 30].
The main disadvantage of LAK cells, is that they release
multiple cytokines (IFN-γ, tumor necrosis factor-α (TNF-
α)), which cause many of the unwanted pharmacological
toxicities associated with this clinical therapy.
2.1.4. γδ TC e l l s .Normally the T cells that we think about,
are those T cells with the classic αβ T-cell receptor (TCR)
rearrangements. These cells normally circulate through the
blood and reside in the lymph nodes and spleen. These cells
reside in many tumors as the tumor-inﬁltrating lymphocytes
(TILs). But another cell type also goes through the same
thymus-education pathway, except that these cells utilize
their rearranged γδ T-cell receptors to recognize their
antigens. These γδ T-cell receptors are more restricted in
their TCR diversity and are not MHC restricted, although
theymayrecognizenonclassicHLA-EandHLA-Gmolecules.
These lymphocytes were initially discovered to be cytotoxic
towards leukemia cells, but Fujimiya and colleagues [31] dis-
covered that these cells also had the ability to recognize and
kill glioma cells in vitro. Several of the ligands that γδ Tc e l l s
can recognize tumor cells (MICA, MICB, and UL-16 binding
proteins) are also found on gliomas [32]. In the United
States, Lamb and colleagues [33, 34] conﬁrmed the previous
study.Theirhumanγδ Tcellsfailedtokillnormalastrocytes.
They also discovered that the γδ T cells can be expanded in
the presence of low doses of IL-2 and zoledronic acid, so that
suﬃcient number of cells could be generated for infusion
back into patients. Human γδ T cells when implanted into
nude mice showed immunological eﬃcacy against U251
xenografts [35]. This non-MHC restricted killing by γδ T
cells opens up the possibility that allogeneic donors could
be used for therapeutic purposes in gliomas without risking
the possibility of graft-versus-host reactions or autoimmune
diseases. Clinical trials using this approach against brain
cancers are expected to begin in the summer/fall of 2011 at
the University of Alabama, Birmingham.
2.1.5. Gene Therapy. Gene therapy using various cytokines
and costimulatory molecules was used in experimental
glioma models to induce stronger immune responses. IL-
2a n dI F N - γ transduced rat RG2 (also known as D74)
glioma cells, when injected into the brains of na¨ ıve rats,
resulted in premature death of the rats due to changes in the
vasculature of the brain [36]. Peripheral vaccination using
N32 rat glioma cells transduced with IFN-γ and interleukin
7 induced intracranial rejection of the parental N32 glioma
[37].Themembraneformofmacr ophagecolon ystimulating
factor (mM-CSF) as opposed to the soluble form of M-CSF,
when transduced into T9 (also known as 9L) glioma cells
caused the transduced cells to be immediately rejected [38–
40]. After glioma rejection occurred, tumor immunity was
concurrently induced. These rejected mM-CSF positive cells,
not only lead to excellent prophylactic vaccination, but could
also be successfully combined with antiangiogenic therapy
to therapeutically treat seven-day established intracranial
gliomas [41]. Granulocyte-macrophage colony stimulating
factor (GM-CSF) and interleukin-4 (IL-4) transduced 9L
gliomas also led to tumor immunization under similar
conditions [42, 43]. Since GBM patients relapse so fast, it
wasconsideredunlikely,thatonecouldestablishthepatient’s
primary glioma cell line and then transduce them with
immunostimulatory molecules or cytokines fast enough,
before the glioma relapse occurs. Thus this genetic approach
using autologous gliomas has not been used for neuro-
oncology.
One limitation of using GM-CSF transduced glioma
cells as a tumor vaccine is that some human gliomas make
and use GM-CSF as a potential autocrine growth factor
[44, 45]. So this cytokine must be carefully used, so as not
to enhance the growth of the primary glioma. One way to
avoid any possible GM-CSF-dependent autocrine pathways
by gliomas themselves is to make use of the versatility of
the APC such as dendritic cells (DCs) in an ex vivo setting
using the recombinant cytokine (see below). This way this
recombinant cytokine does not directly interact with the
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2.2. Antigenic Speciﬁc Pathways
2.2.1. Antibody Approaches towards Glioma’s Vasculature.
Angiogenesis is crucial for tumor growth greater than 1-
2mm 3. Multiple growth factors and proteolytic enzymes
play diﬀerent roles in angiogenesis, but which pathway is
the most critical one for any given tumor is still actively
debated. Mostly likely, several antiangiogenic agents are
needed to target multiple sites, simultaneously to shut down
this entire process. Since gliomas are highly vascularized,
these antiangiogenic approaches have a potential to work,
assuming the right glioma and its angiogenic pathway can
be selected. Based upon microarray data analysis [46, 47],
gliomas are classiﬁed into at least three subtypes: classical,
proneural, or mesenchymal. Each form has its own unique
characteristics and survival rates. This data may allow for
better targeting of these types of glioma, once these angio-
genic pathways are identiﬁed for that individual glioma.
We will discuss only the antibodies that are currently being
tried against brain cancer angiogenesis. A number of small,
cell-permeable, receptor tyrosine kinase inhibitors are being
used clinically against brain tumor angiogenesis, but we will
not discuss them here, since they are not immunologically
based. For further references see the current reviews by
[48–50]. There is evidence that some antiangiogenic drugs
can be successfully combined with a tumor vaccine to treat
an experimental one-week established intracranial glioma
[41].
Antivascular Endothelial Growth Factor (VEGF) Pathways.
VEGF was the ﬁrst cytokine to be associated with tumor
angiogenesis. There are four forms of VEGF: VEGF-A,
VEGF-B, VEGF-C, and VEGF-D. These growth factors bind
to two speciﬁc VEGF receptors, types 1 and 2. The Avastin
(bevacizumab)antibodybindsandneutralizestheVEGFand
prevents the cytokine from properly stimulating the VEGF
receptors. Theoretical interfering with this pathway should
prevent the endothelial cell precursors from being recruited
into the growing tumor, thereby blocking early angiogenesis.
There is some association with VEGF-driven pathways
with the mesenchymal type of GBM. Avastin along with
diﬀerent chemotherapeutics did give high response rates
in recurrent gliomas ranging from 43–63% [51–53]. This
combined approach using an antiangiogenic antibody with
chemotherapeutics could improve the eﬃcacy of treatment,
even if Avastin alone has some antiglioma eﬀect [54]. As
a consequence, Avastin has been registered by the FDA in
May 2009 for treatment of relapsing GBM after standard
treatment.
Another antibody is ramucirumab; this antibody targets
the VEGF Receptor 2 [55]. This antibody (IMC-1121B) is
beingdevelopedbyImcloneSystems.InPhaseIstudiesusing
a variety of solid tumors (no glioma patients were tested),
systemic serum VEGF-A levels did rise during the therapy.
Tumor perfusion and vascularity were diminished in most
of the patients that received the ramucirumab as predicted
[55]. For GBM therapy, it would seem that both antibodies
towards VEGF and VEGFR2 could be used together to
completely inhibit this VEGF-mediated pathway.
Antihepatocyte Growth Factor/Scatter Factor (HGF/SF). As
its name implies, this cytokine/growth factor was initially
discovered in liver cancers. But gliomas make this protein
and use it as an autocrine cytokine by binding to its receptor
called c-Met [56]. Upon binding its receptor, HGF/SF is
thought to stimulate the invasive behavior of the gliomas.
Amgen has developed the AMG102 antibody, which has
in vivo eﬃcacy against human U87 gliomas growing in
immunodeﬁcient mice [57]. We are not aware of any current
clinical trials being performed for neuro-oncology with this
antibody.
2.2.2. Antibodies Directed towards the Glioma
Antiepidermal Growth Factor Receptor (EGFR) Antibodies.
EGFR is a predominant pathway that helps characterize the
classical/proliferative type of gliomas. These receptors bind
either to EGF or transforming growth factor-α (TGF-α).
These receptors can either be mutated or overexpressed due
to genetic ampliﬁcations. The most common mutation of
the EGFR is the EGFRvIII mutation, caused by a deletion of
268aminoacidsintheextracellularregionthatconstitutively
activates this receptor. At least 2 diﬀerent antibodies towards
this receptor are currently used for clinical studies: Cetux-
imab/Erbitux [58] and Nimotuzumab [59]. A preclinical
model showed promise in immunodeﬁcient mice [59], but
this success was not observed in clinical trials [60].
Antiplatelet Derived Growth Factor Receptor α (PDGFRα)
Antibody. The PDGFRα-mediated pathway is representative
of the proneural subclass of GBM. This receptor can bind
either to PDGF-AA, PDGF-AB, PDGF-BB, or PDGF-CC
[61]. Again, PDGFR is ampliﬁed and overexpressed in some
GBM. The IMC3G3 antibody is being explored as a clinical
therapy for this receptor. Cytomegalovirus (CMV) has been
linked with human GBM [62] (see viral antigens). CMV
is reported to use the PDGFRα as an attachment factor
[63]. This antibody may be clinically signiﬁcant, because it
inhibits growth factor stimulation of the glioma along with
interfering with CMV infections. One other advantage of
targeting the PDGF receptor is that it can also target the
pericytes/ﬁbroblasts which give structural support to the
endothelial cells [64]. This antibody may also interfere with
the antiangiogenic pathway, too.
Tenascin C. Tenascin C is a glycoprotein speciﬁcally made
by gliomas. It is laid down as an extracellular matrix.
Monoclonal antibodies towards tenascin-C (clone 81C6)
[65] by Duke University or the BC-2 and BC-4 clones
used at Bufalini Hospital (Cesena, Italy) [66, 67]h a v eb e e n
developed and are capable of localizing to various GBM in
patients. Attempts have been made to use radioisotope (I131,
Y90 or At211)-conjugated antibodies to treat gliomas. When
these antibodies were injected into their respective patients,
these antibodies localized to the glioma. In theory, the
radiation released from the isotope-labeled antibody should
damage and kill the adjacent cancer. To date some successes
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Italian cohorts using these radiolabeled antibodies [65, 66].
These antibodies will probably be quite useful for ﬁnding
residual pockets of the tumors. Since the tenascin c is not
strictly a glioma membrane protein, this may be a limiting
factorforthedirectgliomatreatment,andisprobablynotthe
optimal way to treat glioma cells. Another possible problem
withthisoverallapproachisthatGBMstemcellsareresistant
to the eﬀects of radiation (see GBM stem cells).
Bispeciﬁc Antibody. In the 1980’s the concept of using bispe-
ciﬁc antibodies came into vogue. Here two diﬀerent mono-
clonal antibodies are used, the ﬁrst antibody binds speciﬁ-
cally to the cancer while the second antibody binds the T or
NK cells (via CD3). The antibodies are selectively reduced,
so that a heavy and light chains still remain together as a
heterodimer, maintaining the antibody binding speciﬁcity.
Then the single heavy/light chain from the ﬁrst antibody is
mixedtogetherwithanidenticallypreparedsecondantibody,
which binds to the cancer cell’s surface. Afterwards, the two
heterodimers are allowed to reform their disulﬁde bonds,
producing a stable antibody now with two diﬀerent antigen-
binding speciﬁcities. The bispeciﬁc hybrid antibody is
selected, which simultaneously binds to both cells/antigens.
Thus using this bispeciﬁc antibody, the eﬀector lymphocyte
now physically binds to the cancer cells and helps initiates
cytolytic function by the lymphocyte against the cancer.
Nitta et al. [68] used a bispeciﬁc antibody towards CD3
and a tumor antigen, originally developed against lung
cancer (NE150, 69). But NE150 also had cross-reactive
properties towards human gliomas. When they used this
bispeciﬁcantibodywithLAKcells,thisgroupachievedbetter
clinical responses against gliomas (four out of ten patients
showed tumor regression within 10–18 months), while all
eight patients treated with LAK cells alone showed tumor
recurrence. This study using bispeciﬁc antibody seemed
successful, but it was very labor intensive in the biochemical
preparation. It was deemed impractical to generate suﬃcient
antibody to treat multiple patients in order to demonstrate
statistical signiﬁcant improvement in a larger study. But the
proof of concept here was established with this study.
Single-Chain Variable Fragmented Antibodies. Antibodies
haveamolecularweightof150,000kd,sotheirabilitytopen-
etrate deeply into tumors or tissues is thereby limited. With
the advent of genetic engineering, one can take hybridoma
cells and isolate the mRNA for the antibody. The variable
binding regions of the N terminals (ﬁrst domains) of the
heavy and light chains can be genetically cloned and ligated
together to maintain their ability to bind to the antigen. So
theterm,single-chainvariableantibodyfragment(scFv),was
coined. These recombinant molecules are now only about
25kd in size, which in theory should be able to penetrate
between cells better than normal antibodies. Early studies
were used against the EGFRvIII protein [69, 70]. Improved
tumor penetrance by this scFv was noted. Recently, this tech-
nique has been used with a phage-display technology to pro-
duce unlimited amounts of this recombinant protein. Last
year, Kuan et al. [71] used this technique to make scFv that
targetthemultidrugresistanceprotein-3(MRP3)genefound
ongliomas.Theserecombinantproteinshadverygoodbind-
ing aﬃnities for gliomas and could be able to be conjugated
with either drugs or radioisotopes. Since this MRP3 speciﬁc
scFV targets a key biological response (reverse chemothera-
peutic drug transporter), this scFV should be combined with
chemotherapy to generate synergistic clinical eﬀects.
Antibodies on the Horizon. Two antibodies (ipilimumab and
daclizumab) are on the horizon, which could have potential
impact on glioma immunotherapy. Ipilimumab is the anti-
body that targets an immunomodulatory molecule, called
CTLA-4. When na¨ ı v eTc e l l sb e c o m ea c t i v a t e d ,al a t ea n t i g e n
called CTLA-4 is expressed. CTLA-4 then binds and inhibits
the CD28 costimulatory pathway. Thus, this molecule natu-
rally represses T cells. By preventing this CTLA-4-mediated
downregulation, an enhanced immune response can be
sustained and can probably enhance antitumor immune
responses. Recently, this antibody has been successfully used
forthetreatmentofmelanoma[72].Hereanadditional,four
months of survival were noted in these patients.
The second antibody is Daclizumab, which targets the
high-aﬃnity interleukin-2 receptor-α on T cells. This is
another potential monoclonal antibody that can improve
patient survival by preventing the actions of T-regulatory
cells. T-regulatory cells (Treg) are IL-2Rα+ (CD25) cells
and thus more sensitive to the antibody compared to the
cytotoxic T cells (see below). By eliminating Treg cells, a
more sustained antitumor immune response can also be
maintained. Here the idea is to eliminate the Treg before
they inhibit the an optimal antiglioma immune response. In
experimental models, eliminating Tregs improves therapeu-
tic eﬃcacy of immunotherapy [73]. It will not be long before
either of these two antibodies will be combined with some
clinical trial to improve glioma therapy.
IgE? An unexpected discovery was initially reported by
Wrensch and colleagues [74, 75]. Here atopic patients who
frequently suﬀer from immediate hypersensitivity reactions:
hay fever, asthma have a lowered risk of contracting gliomas.
Those patients who have high serum levels of IgE and who
do develop glioma, statistically survive somewhat longer
than those patients with low IgE levels. These studies
have been reproduced in a larger meta-analysis and seem
highly credible [76]. IgE is the antibody that mediates
immediate hyper sensitivities. Nothing is known about how
the degranulating basophils and mast cells responding to
IgE-mediated cross-linking aﬀect glioma cells or the glioma’s
vasculature. So this phenomenon could prove to have major
repercussions for future glioma therapy. Genetic engineering
with some of the antibodies described above could be
constructed using the IgE framework. Most IgG antibodies
work therapeutically when applied in the milli to microgram
range, while immunopharmacological eﬀects of IgE occurs
in the nano to picogram range. Thus, these redirected
antibodiesmighthaveuniquepropertiesinachievingclinical
eﬀects at lower doses than the IgG-based antibodies. Of
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and require stringent animal safety tests to assure that
animals and then patients do not immediately go in acute
anaphylactic shock upon contact with gliomas. Nevertheless,
this is a very intriguing concept.
2.2.3. Cellular Approaches. After the nonspeciﬁc LAK cell
experience in the mid to late 1980’s, the next progression of
cellular immunotherapy was to use those tumor inﬁltrating
lymphocytes (TIL) and the eﬀector T cells that are found
in the local lymph nodes draining the tumor. These T cells
were already primed in vivo towards the patient’s own tumor
cells. This methodology was developed in the days prior to
our current understanding and routine use of dendritic cells.
Here TILs were selectively expanded from either the tumor
or draining lymph node cells, by using IL-2, supplemented
with LAK-conditioned supernatant as a source of other T-
cell immunostimulatory cytokines [77]. By routinely restim-
ulating these cells with irradiated or killed tumor cells, this
helped maintain T-cell speciﬁcity. When reinfused back into
the patients, the CD8+ CTLs had the inherent advantage
over the LAK cells, in that these CTLs were capable of
killing multiple target cells. CTLs only release their cytokines
when properly stimulated by the self-MHC and peptide.
These T cells reduced much of the clinical toxicity previously
seen with LAK cells. CD8+ CTL were often the cell of
choicetoexaminesincetheireﬀectorfunction(cytolysis)was
easily measured by radioisotope release assays. This TIL/CTL
approach again proved to be somewhat better at generating
clinical responses to melanoma and renal cancer [77].
In rodent models, the use of TILs and draining lymph-
node-derived T cells expanded ex vivo d i dp r o v et ob ee ﬃca-
cious for the treatment of rodent gliomas [78–80]. Dunn et
al. [81] have recently reviewed the history of clinical glioma-
based T cells in better details; readers are encouraged to read
this article. GBM TILs were successfully used by Quattrocchi
etal.[82]totreattheirpatients,wheretheytookTILsderived
from recurrent malignant gliomas and expanded the CD3+
Tc e l lin vitro with IL-2. Both CD4+ and CD8+ cells were
expanded and then reinfused into the surgical cavity via
an Ommaya reservoir. After the infusion of the T cells, the
patient was given IL-2 maintenance therapy, three times a
week for a month. There was one complete responder (45
months) out of 6 patients treated. Plautz et al. [83] also
showed some clinical successes using immunized T cells
obtained from inguinal lymph nodes and expanding them
with a mitogen [83]. After a short-term ex vivo expansion
these cells were then reinfused back into the patient.
Allogeneic Mixed Lymphocyte Reactive T Cells. Another
lymphocyte approach towards brain cancers was pioneered
by Kruse et al. [84] and reviewed in Yang et al. [85].
Herelymphocytesderivedfromhistoincompatibleallogeneic
human blood donors are combined with the patient’s irra-
diated lymphocytes. A mixed lymphocyte reaction sensitizes
the allogeneic donor’s peripheral blood mononuclear cells
towards the patient’s MHC. These alloactivated T cells are
then expanded in low doses of IL-2 for another 2-3 weeks.
These alloactivated lymphocytes are cytotoxic towards the
patient’s lymphoblasts. When these eﬀector cells are then
implanted into the resection cavity, these CTLs can eliminate
the remaining glioma cells. This procedure was repeated up
to 5 times for each patient. Some long-term (>15yr) sur-
vivors were documented against stage III gliomas [86]. Early
concerns that these allospeciﬁc CTLs would indiscriminately
kill nontumorous host brain cells and induce autoimmunity
have been proven to be unfounded. Thus, a larger dose-
escalation study using this technique for stage III astrocy-
tomas is open for accrual for 15 patients in the southern Cal-
ifornia area in collaboration with Dr. Linda Liau (UCLA) to
expand and conﬁrm the validity of this therapeutic modality.
T-Helper Cells. CD4+ T cells also have important antitumor
immune eﬀector functions. CD4+ cells recognize MHC class
II restricted peptides. Some CD4+ T cells can kill tumor cells
either via Fas Ligand-dependent [87] or perforin-dependent
pathways [88] .B u tm o s tt u m o r sd on o te x p r e s sM H Cc l a s sI I
antigens, so how antitumor eﬀects are directly mediated by
these T cells is not really known. The CD4+ cells’ probable
mechanism of action involves the release of cytokines and
other mediators, which either targets the tumor directly or
the tumor’s vasculature. The best possibility is that as a result
of stimulation by the DC, these CD4+ cells release cytokines
(IL-2, IL-6, IFN-γ, TNF, lymphotoxin (LT)) that assist in the
expansion of the CD8+ CTLs. Some cytokines released from
type 2 helper T cells (Th2) can assist in B-cell activation and
maturation into making speciﬁc IgG antibodies. In the rat
9L (also known as T9) glioma model, eﬀective immunity
was seen by the adoptive transfer of immunized CD4+
T cells [39, 89]. Furthermore, Okada et al. [90] showed
that rats immunized with IL-4-transduced 9L gliomas did
make antibodies against at least three rat glioma-associated
proteins, not previously known to be glioma-associated anti-
gens. In a humanized SCID mouse model, CD4+ T cellswere
isolatedfromamousethatwasactivelyrejectingamembrane
isoform of macrophage colony stimulating factor (mM-CSF)
transduced U251 glioma [91]. But no exact mechanisms
were provided in these last studies, explaining how the direct
beneﬁcial role of CD4+ T cells occurred in these glioma
models other than by the “classic” T-helper cell function.
T-Regulatory Cells. Gliomas frequently contain T-regulatory
(Treg) cells [92–94] which are CD4+, CD25+ (IL-2Rα+),
and FoxP3+ cells. These cells are probably induced in an
eﬀort to maintain immune homeostasis. In the gut, these
types of cells also can be induced into becoming follicular
helper T cells that assist B cells into making IgA [95].
Because of microenvironmental conditions in the glioma
such TGF-β and PGE2, these T cells are forced to become
these suppressor types of cells. These Treg cells inhibit T-
cell eﬀector functions; this might account for the failure of
GBM-derived TILs to successfully eliminate the glioma in
clinical trials. Tregs work in several ways [92–94] to inhibit
the necessary antitumor eﬀector mechanism. Methods to
eliminate Treg function will likely improve clinical results
in future trials. Currently antibodies against the IL-2Rα
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earnest investigation of Treg in cancer has blossomed in the
last ﬁve to seven years. So it is unknown what percentage
of Tregs was previously expanded as TIL populations and
inadvertedly used in previous clinical TIL studies, which
most likely failed to treat these patients.
T-reg cells and another type of T-helper cell, called Th17
cells, seem to share a common early stage pathway [96, 97].
Na¨ ıve T cells upon exposure to antigen and TGF-β can give
risetoeitherTregorTh17cells.TogetTh17cellsthepresence
of IL-6 is required. Both cytokines are produced by gliomas.
Recently, Th17 cells were described in murine and human
gliomas [98], but their beneﬁcial or inhibitory actions was
not elucidated. In a mouse model of melanoma, Th17 cells
couldbeusedtoeliminateverylargeestablishedtumors[99].
Redirected T Cells Using Chimeric Antigen Receptors (CARs).
Generating T-cell clones responding towards tumor-speciﬁc
antigens either by TILs or by DC restimulated T-cells clones
is quite labor-intensive and naturally quite costly. The
potential for microbial contaminations and incubator/power
failures increases with time. This logistical problem lead to
the concept of redirecting T cells or NK cells by genetically
manipulating these eﬀector lymphocytes by using man-
made chimeric antigen receptors (CARs). The same basic
technology described for scFv antibodies can now be
married to lymphoid eﬀector cells. Here one splices the scFv
region via a spacer region to the transmembrane spanning
regions of the CD28 molecule. The intracellular region of
TCRζ chains is also ligated into this construct. This artiﬁcial
receptor, when activated upon proper T-cell surface-binding
to the tumor, initiates cytolytic T cell function (release of
perforin/granzymes or cytokines). These kinds of genetically
engineered receptors have also been called zetakines or
T-bodies.
These redirected T cells can recognize a tumor’s cell-
surface molecule. Other advantages of using CAR constructs
are (1) independent of HLA expression where HLA is
frequently down regulated or eliminated on the gliomas; (2)
can react better to modestly expressed tumor targets; (3)
CARs have uniformity and high-degree of expression; and
(4) reliably generate T cells in a relatively short time for
clinical usage (10–15 days as opposed to 10–12 weeks needed
for CTLs).
Chimeric antigen redirected (CAR) T cells have been
developed, so that they can bind to the IL13Rα2[ 100], her2
receptor [101], EGFRvIII [102] or to the ganglioside GD3
[103]. Figure 1 shows the current forms of CAR currently
used for possible therapy of human gliomas. After the CAR
construct is engineered, then the gene is packaged within
either adenoviral or retroviral vectors. This allows one
to quickly transfect as many patient’s T lymphocytes as
possible. When these transduced peripheral blood T cells
are reintroduced back into the patient, preferably near or in
the cancer inside, the CAR-redirected T cells can attack the
cancer. IL-13Rα2 based CAR/zetakine transduced T cells kill
several human glioma cells in vitro and appear eﬀective in
intracranial gliomas in immunodeﬁcient mice. With her2
speciﬁc CAR lymphocytes, therapeutic eﬃcacy was seen in a
xenogeneic model with the Daoy (her2+) medulloblastoma,
when these human CAR T cells were adoptively transferred
into these mice [104]. Her2 CAR constructed human T cells
killedbothCD133+andCD133-GBMcells.Her2-redirected
CAR T cells showed some eﬃcacy against the human her2+
gliomas growing in SCID mice [101]. The advantage of using
CAR-T cells is that they are also applicable towards other
cancers like her2+ breast and ovarian cancers; EGFRvIII+
engineered CAR T cells can also target lung cancers;
while ganglioside GD3 CAR-T cells can also interact with
melanoma cells. Currently CAR T cells are being used
clinically at the City of Hope (Duarte, Ca) and the clinical
trial using the CAR-her2 cells is expected to start recruiting
patientsinthemid-lateFallof2010attheCenterforCelland
Gene Therapy of Baylor College of Medicine (Houston, TX).
Dendritic Cell-Based Vaccines. Dendritic cells (DC) are cur-
rently the favorite therapeutic modality now used in cancer
immunotherapy. Monocytoid dendritic cells are readily
available from the peripheral blood monocytes and can be
quickly activated ex vivo using cytokines as granulocyte-
macrophage colony stimulating factor (GM-CSF) and inter-
leukin 4 (IL-4). This technique is quite versatile in that
diﬀerent sources of antigens can be added to the DC. Killed
tumor cells, tumor cell extracts, puriﬁed tumor mRNA, or
puriﬁed tumor antigens can be given to the DC and these
cells can then properly process the tumor antigens, so that
thepeptidesarepresentedintheMHC.TheseDCarecapable
of immunizing na¨ ıve animals [105–107]. Plasmacytoid DC
cells are beginning to be used for cancer immunotherapy
[108], but so far, they have not been developed for brain
cancer therapy. Once ex vivo activated and antigen-pulsed
DC are generated, some protocols allow the non-matured
DC or matured DC to be injected back into their patients.
The non-matured DC are thought to become mature after
reintroduction back into the patient, especially after the
injection of the TLR antagonists, which act as an adjuvant
to cause DC maturation.
Worldwide there are multiple centers [109–114] generat-
ing DC used for brain cancers. Clinically positive responses
for usually reported for a subset of glioma patients. Usually
this means that the mean time to progression for these
treated patients with high grade gliomas increased in these
responder populations. Kim and Liau [115] reported that
their vaccine responders survived 642 ± 61 days when
compared to the non-responders (430 ± 50 days). Disease
free progression was also improved by 4.5 months. Some
patients are reported to survive more than ﬁve years. One
key ﬁnding that has been repeatedly reported is that this DC-
based immunotherapy is safe with few serious side eﬀects.
A variant of the dendritic cell-based vaccine occurs by
fusing the DC with the glioma cells to form an immunos-
timulatory cellular hybridoma. Here the DCs are fused with
the autologous glioma cell line. This strategy is analogous
to the classical hybridoma used for antibody production,
except the end function of this hybrid is to stimulate an
immuneresponse.Thegliomaparentcellsuppliesthecorrect
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speciﬁc immune response. The DC parental cell provides
the machinery to take the glioma antigens, and process the
peptides onto the patient’s MHC (HLA-A, B, C, and D loci).
TheDCparentalsosuppliesthecostimulatorymoleculesand
cytokines to make this hybrid an immunostimulatory cell.
When these x-irradiated hybrid cells are injected back into
the patient, they now provoke an immune response, so that
multiple Tclones responding tomultiple gliomaantigens are
elicited. In clinical studies, Kikuchi and colleagues used this
approach to treat 6 patients [116]. This ﬁrst study showed
this hybridoma vaccine was safe, but it failed to achieve any
clinical eﬀect. In the follow-up study, the DC hybridoma
was combined with an injection with recombinant IL-12, 3,
and 7 days after the hybrids were injected. This combination
achieved some disease stabilization and tumor shrinkage in
fouroutof15patientsthatweretreated[117].Afteroneyear,
two of the patients still survived.
Finally,oneaspectofDCthatisnotnowfullyappreciated
is that IL-4/GM-CSF activated human DC can kill glioma
cells [118]. Both human and rodent DC can directly kill
human gliomas either by direct contact or by the release of
nitric oxide. Others have previously reported this cytolytic
phenomenon towards other human cancers [119, 120]b y
t h er e l e a s eo ft y p eIo rt y p eI Ii n t e r f e r o na n dm e m b r a n e
cytolytic-inducing molecules (i.e., TRAIL, NKG2D, Fas
Ligand). No one is currently using activated DC as the
actualcytolyticeﬀectorcellsagainstglioma.Mostresearchers
consider the best use of DC is to stimulate T-eﬀector cells by
as y s t e m i cv a c c i n a t i o nr o u t e .
3. Tumor Antigens
Identiﬁcation of clinically relevant tumor antigens is actively
researched. New tumor antigens seem to be reported
monthly. Tumor antigens are identiﬁed by either antibodies
orbyTcells.ThelatterarerecognizedbyTcellsinthecontext
of the TCR with either MHC class I which are recognized
with the help of CD8+ molecules or MHC class II that
are recognized by CD4+ molecules. Cheever and colleagues
[121] have recently prioritized a set of 75 human tumor anti-
gens, which they determined should be further developed
for cancer immunotherapy. This prioritization was based
on a number of key factors, such as possible therapeutic
function, the immunogenicity of these molecules, their roles
in oncogenesis, its speciﬁcity, and its frequency in a number
of cancers. At least 18 of these listed tumor antigens are
pertinent to human brain cancers.
Tumor antigens can be deﬁned as either being tumor-
speciﬁc or tumor associated. Tumor-speciﬁc antigens are
actually rare, while tumor-associated antigens are expressed
on normal tissue and are simply overexpressed by the tumor.
Table 1 lists the antigens that can be considered glioma-
associated antigens. Surprisingly, there are really no truly
glioma-speciﬁc antigens currently known. All these antigens
can be found within a variety of other tumor types. But
from experimental evidence, we know there is tumor speciﬁc
immunity. So there are undoubtedly many glioma-speciﬁc
and glioma-associated antigens still to be found.
3.1. Tumor-Speciﬁc Antigens. Tumor-speciﬁc antigens in-
clude p53, EGFRvIII and ras mutations. These antigens
are quite common in many types of cancers. Gliomas
rarely have ras mutations, but frequently possess p53 point
mutations, which inactivate its normal function. Mutated
p53 can be recognized by murine CTLs by wild type-p53
peptides that bind to MHC class I alleles [123]. Human
CTLs responses towards p53 can also be developed in an
identical fashion [124, 125]. Many cancer patients possess
discernable antibody responses to p53 [126], so some
Th2-mediated responses generated towards MHC class II-
restricted antigens are needed to help produce these higher
aﬃnity IgG antibodies. Many glioma antigens are called
“antigen recognized by T cells” (ART), for example, ART-
1, ART-4, or “squamous antigen recognized by T cells”
(SART);thatis,SART-1,-2,and-3.Theselast5antigenswere
identiﬁed within either glioma cell lines or within adult or
pediatric brain tumors [127].
3.2. Overexpressed Antigens. These antigens are found in
normal cells and tissue, such as B-cyclin and CD133. These
antigensappeartobeoverexpressedontheircancerouscoun-
terparts. Some antigens are found only within the testes and
cancers. Hence the term “cancer-testes antigen” is frequently
given, to describe them. Some of these antigens include
Mage-1, Gage-1, SSX2, and NY-Eso-I. These antigens are
found in terminally diﬀerentiated melanocytes and in their
transformed progeny (melanomas) and in gliomas. Some
diﬀerentiation antigens are not found in the testes, but are
found on normal cells like melanocytes and in melanomas
and in gliomas, with Trp-1, and Trp-2 being representative
ofthisgroup.Sincemelanomasandgliomacellsshareacom-
mon embryonic neuroectoderm precursor, it is not that sur-
prising that these two cancers share many common antigens.
3.3. Viral Antigens. Many viruses are thought to play a
causative role in some human cancers: HTLVI, hepatitis B
and C virus, EBV, and papilloma virus. Recently, Cobbs
and his colleagues [62] linked cytomegalovirus (CMV)
with human gliomas. CMV is frequently detected within
chronically immunosuppressed patients with either trans-
plant patients or in late stage HIV infections suﬀering
from Acquired Immune Deﬁciency Syndrome (AIDS). It
is thought that 70–90% of the population are previously
exposed to CMV and might be chronically infected with
this virus. Our immune systems keep this virus under tight
control. Glioma patients are frequently considered immuno-
suppressed by a number of mechanisms [128]. So when
the immune system is impaired as in GBM, the CMV can
now reappear. Whether CMV directly causes glioma is a
controversial topic. The possibility that CMV attaches itself
to glioma via the PDGFRα allows some interesting therapies
to be explored. Viruses are usually good targets for the
immune system. One CMV antigen, pp65, induced human
HLA-A2 immune responses in a GBM patient [129]. Freshly
isolated glioma samples seem to express this antigen to a
high degree [130], but cell lines lose expression of CMV. If
a high number of GBM cells do attract and harbor CMV inClinical and Developmental Immunology 9
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Figure 1: Chimeric Antigen Receptors (CAR) used for potential human therapies of brain cancers. The monoclonal antibody towards either
her2/neu, EGFRvIII, ganglioside GD3, or IL13Rα2 is the initial source of the genetic material. The ﬁrst domains of the heavy and light chains
are ligated together with a short spacer region to create the single chain variable fragment (scFv), to preserve the recombinant proteins’
antigen binding region. Another spacer region is ligated from the scFV region to the transmembrane CD28 molecule, followed by the TCRζ
chain. After the T cells are transfected with the adenoviral construct, these T cells are then allowed to interact with the tumors. Upon contact
with the antigen on the tumor, the CAR is activated and the TCRζ chain is now activated which then stimulates antitumor mediator eﬀector
function, that is, cytolysin or cytokine release.
Table 1: List of tumor-associated antigens known within human brain cancers.
Aim-2 Art-1 Art-4 B-cyclin CD133 EGFRvIII
Epha2 Ezh2 Fosl1 (fra-1) Gage-1 Galt-3 Ganglioside GD3
Gp100 GnT-V Her2 HNRPL IL-13Rα2L i v i n
Mage-A1 Mart-1 MELK MRP-3 NY-Eso-1 Prame
PTH-rP Sart-1 Sart-2 Sart-3 Sox 2 Sox10
Sox 11 SSX-2 Survivin Tert TRP-1 TRP-2
Tyrosinase Ube2V Whsc2 WT-1 YKL-40
SLC01C1∗ BCAN∗ CHI3LI∗ CLIP2∗ FABP7∗ NR2E1∗
NLGN4X∗ NES∗ NRCAM∗ PDPN∗
Asterisk denotes potential tumor antigens described in [122].
vivo, then this opens up the possibility of developing CMV
peptides to vaccinate against the virus and therefore the
glioma is targeted indirectly. Currently, Duke University is
actively using DC-based vaccines targeting CMV antigens to
treat their patients who are CMV positive. Clinicians at Penn
State University are using allogeneic CMV-speciﬁc CTLs to
treat their glioma patients [131, 132]. The Center for Cell
and Gene Therapy of Baylor College of Medicine is also
developing a CTL approach against CMV as the way to treat
GBM, these clinical trials will shortly begin in the next few
months. Finally, another possibility is to use the CMV virus
as a vector to deliver therapeutic agents or genes speciﬁcally
into these gliomas to make them more vulnerable to assorted
therapies. Thus, CMV may be a very useful immunological
tool to attack GBM.
4. Source of Antigenic Materials
The choice of a source of the tumor antigen is probably
the most important decision to be made when it comes to
vaccinating cancer patients. There are multiple sources of
antigenic material: cell lines (whole cells or lysates), fresh
surgical tissue (cell lysate, mRNA, or primary cultures of
tumor “stem cells” grown as neurospheres), and peptides
(acid eluted or synthetic). Each choice has its own pros and
consfortheirclinicalusefulness.Theknowledgegainedfrom
these clinical studies using cell lines, neurospheres, surgical
specimens, and peptides will undoubtedly advance the ﬁeld,
once we determine what the best source of tumor antigens is.
Unfortunately, only trial and error will tell us the best source
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4.1. Cell Lines. Traditionally, cell lines were used for exam-
ining immunization properties either in animals or in early
clinical trials. These cells generally represent a stable and
continuous source of tumor cells and they can reproducibly
form cancers in experimental animals. Additionally, these
cells can be modiﬁed with cytokines or costimulatory
molecules to improve their immunogenicity. Cell lines
created from the 1960 to 1980’s are still widely used:
Uppsala Sweden-derived cells (U87, U251, U373, etc.), Duke
University-derived (D54, D68, etc.), Lucerne Switzerland-
derived (LN18, LN 229, etc.), Surgical Neurology Branch
(Bethesda, MD)-derived cells (SNB19) are still quite useful
for studying various aspects of glioma biology both in vitro
and in vivo within immunodeﬁcient mice. These glioma cells
readily form either intracranial or subcutaneous tumors in
these immunocompromised mice. SCID/NOD mice can be
“humanized”bypriortransplantationofhumanthymusand
bone marrow. One can examine human immune responses
in vivo without doing expensive clinical trials, while quickly
exploring the feasibility of generating these human-speciﬁc
responses.
Established cell lines can either be used as whole-cells or
asalysatetobetheimmunogen.Celllysatescanbecombined
with adjuvants or it could be used as an irradiated whole
cell. Cell lines can be genetically modiﬁed with cytokines or
costimulatory molecules to improve the immunogenicity of
the cells. Parney and colleagues [133, 134] have shown this
possibility of genetically engineered glioma vaccines within
immunodeﬁcient mice.
Zhang and colleagues [135], examined 20 human GBM
cell lines, some well-established cells such as U87, U251,
D54, LN18, SNB19, and so forth, along with some recently
derived cells (NovaRx: NR203, 206, etc.). These glioma cell
lines were characterized for their tumor antigen expression
of 20 tumor-associated antigens by quantitative reverse-
transcriptase real-time polymerase chain reactions (qRT-
PCR) techniques. The translated proteins were conﬁrmed by
immunoﬂourescent antibody staining and intracellular ﬂow
cytometryfor16 tumorantigens, sincethoseantibodies were
available. With the exception of 3-4 antigens, the cell lines
were all quite homogenous and had high tumor-associated
antigen mRNA expression. Hence a cell line or combination
of cell lines can easily be used as a universal source of
antigenic material for any potential vaccine. Besides the
currently known tumor-associated antigens (Table 1), the
other advantage is that cell lines can also be a source of
currently undiscovered antigens. Zhang et al. [127] showed
that surgical specimens derived from adults with GBM were
highly antigenic (29 antigens were routinely expressed),
while the surgical specimens derived from pediatric GBM,
ependymoma,pilocyticastrocytomasweremorerestrictedin
their tumor antigen proﬁle (9–16 antigens).
Cell lines grow quite easy and can be produced in bulk
in an economic manner. To use them as a clinical product,
one needs to do extensive clinical testing for all types of
pathogens (mycoplasma, bacteria, fungi and viruses). Some
safety testing takes the cells/cell lysates and exposes them
to other human/animal cells, injected into suckling mice,
guinea pigs, and chicken eggs to assure no cryptic pathogens
are present when grown in a more permissive environment.
As expected this procedure is quite expensive ranging from
US $50–80K/cell line. This procedure is required, if the
vaccine material from one person is being injected into a
diﬀerentpatient.Butiftheautologouscellsarecustom-made
forthatgivenpatient,thenthisaddedsafetytestusuallyisnot
required for the exotic viral pathogens. Only the common
microbial contaminants need to be tested. This ﬁnancial
restraint helps explain why most current protocols are using
autologous gliomas. A cell lysate is made directly from the
resected surgical specimen, so the risk is minimized for
possible microbial contamination. Currently twocompanies,
NovaRx (San Diego, CA, USA) and Epitopoietic Research
Corporation (ERC, Gembloux Isnes, Belgium) are develop-
ing allogeneic-based vaccines. NovaRx is developing whole
cell line vaccines by knocking down the glioma’s ability to
make TGF-β. Thus, shutting down the ability of these cells
that lead to immunosuppression, and this leads to improved
in vivo responses [136]. This irradiated whole-cell-based
vaccineisknownasGlionix.TheGlionixhasbeensafelyused
to vaccinate six patients and the results were encouraging, so
that further Phase II/III studies are currently being initiated.
ERCisdevelopingacelllysateapproachbycombiningtumor
lysates from a number of GBM specimens. This company is
currently accumulating glioma tissue to be used for their cell
lysate-based vaccine.
An early success using cell lines as a source of tumor
vaccines was reported in the early 1980’s when the Duke
University group used D54 and U251 cell lines to vaccinate
human glioma patients [137]. Some vaccinated patients
becamelong-termsurvivorsafterbeingvaccinatedwiththese
irradiatedwholecells.TheuseofthekilledU251(HLA-A2+)
cells was reported to be the most eﬀective, when compared
to the D54 (HLA-A3+) vaccine. Unfortunately, this study
proved to be premature and illustrated the “growing pains”
of the ﬁeld. It is now felt that patient selection, such as using
patients with lower grade gliomas, better prognosis status, or
younger patients with a better survival prognosis (proneural
GBM subtypes) were used with the U251-based vaccine.
The human glioma cells used for that clinical vaccination
were cultured in fetal calf serum (FCS), which is routinely
used for tissue culture. When the vaccinated patient’s
sera were tested, most patients had antibodies against the
bovine proteins found in FCS [138]. Antibodies against the
immunizing glioma’s HLA antigens were additionally found.
One patient had an undeﬁned antibody speciﬁc for the
U251cells.Thisworkclearlyshowedthathumoralimmunity
was induced within these patients by using an irradiated
whole cell vaccine. Whether the FCS acted as a xenogeneic
adjuvant or as a mechanism of “epitope spreading” [139]i s
an intriguing possibility.
4.2. Stem Cell Lines. The discovery of proper cell culture
techniques for growing “stem cells” or “cancer initiating
cells” as neurospheres has helped advance the ﬁeld of glioma
biology. Here surgically removed tumor cells are dissociated
and grown in serum-free media containing epidermal
growth factor and basic ﬁbroblast growth factor [140].Clinical and Developmental Immunology 11
The concept of “glioma stem cell” has emerged as a hot
topic. Many of the features seen in clinical glioma are
better reproduced when the CD133+ stem cells, rather
than those coming from established cell lines are injected
into immunodeﬁcient mice. Only 10–100 of these cells are
needed to form tumors in these mice within 30–60 days.
The resulting gliomas derived from CD133+ cells display
an invasive phenotype, as opposed to well-circumscribed
borders that form when established (diﬀerentiated) cell
lines are used. GBM stem cells can also explain why gliomas
resist certain drugs and radiation [141, 142]. CD133 was
initially described as a marker which resisted the uptake
of ﬂuorescent markers, which coincidentally resemble
chemotherapeutic drugs [143]. However some GBM stem
cells are also reported as being CD133-negative [144]. So the
whole concept of GBM stem cells is still being reﬁned.
Glioma stem cell lines have been used as a vaccine in
rodent models and appear safe and eﬀective to vaccinate
against some rodent gliomas [145]. Some human glioma
stem cell lines have been characterized for their tumor
antigen proﬁle [146]. With the exception of CD133 for some
stem cells, GBM stem cells possess few truly tumor-speciﬁc
antigens. So it is unlikely we will be able to speciﬁcally
only target stem cells by immunotherapy. Tumor associated
antigens such as TRP2, GP100, EGFR, AIM2, and Sox2 are
present on these human glioma “stem” cells. In contrast, IL-
13Rα2andher2seemstobediminishedinthesehumanstem
cells.
4.3. Surgical Resected Lysates. Tumor lysates are most fre-
quently used, clinically. After the patient recovers 6–8 weeks
from debulking surgery, the patient is leukopheresed to
acquire suﬃcient DC precursors. The debulked tumor was
collected, analyzed and aliquots are saved for vaccinating
protocols with the DCs. This process is relatively simple
and straightforward with minimal risk of contamination, as
opposed to long-term cell culturing.
When glioma surgical samples (WR-GBM) were injected
with Freund’s adjuvant (complete or incomplete) into
monkeys and guinea pigs, an autoimmunity resembling
experimental allergic encephalitis (EAE) was produced
[147]. However, when the glioma cell line that was derived
from WR-GBM (D-68) was used as the vaccine without
Freund’s adjuvant, no autoimmunity was seen. As a result
of these potential autoimmune complications, vaccination
using glioma surgical samples was largely abandoned and
future attempts were usually discouraged by citing this
case. The results using DC pulsed with surgically resected
tissue have been shown to induce tumor immunity without
any signs of EAE [109–115]. This empirical evidence also
overcame the prejudice that was initially elicited from that
prior EAE induction paper [147].
So what are the best sources of antigenic material
coming from cellular sources? Since cell lines and stem
cell neurosphere cultures are pure tumor cells, it would be
expected that these sources would contain the most tumor-
associated antigens, while the surgical specimens are a mix
of tumor cells and normal hosts cells like: endothelial cells,
neurons, microglial, and other hematopoietic cells that were
present within the tumor. These normal cells will therefore
dilute out the tumor antigens coming from the tumor cells.
This is potentially signiﬁcant, because when one uses this
material to pulse dendritic cells, irrelevant normal host
antigensmaybeloadedontothebindinggroovesoftheMHC
molecules, hence stimulating the immune system to a lower
extent. Since there is a ﬁnite number of MHC molecules
per dendritic cell, loading irrelevant peptides may make the
immunostimulatory process to T cells less eﬃcient.
The concept of vaccinating against the tumor’s vascu-
lature was reported [148]. The late Judah Folkman [149]
used to argue that the endothelial cells of tumors are normal
cells. These normal endothelial cells would therefore not
be subject to the same mutational rates as cancer cells. So
these cells would make the best target for cancer therapy,
rather than directly targeting the cancer cells. Virrey et al.
[150] have found that endothelial cells derived from gliomas
are diﬀerent than those endothelial cells derived from the
normal noncancerous brain, these cells have morphological
changes and grow slower than expected. Two recent studies
suggest that GBM “stem” cells can diﬀerentiate into glioma
endothelial cells [151, 152]. So there could be legitimate
reasons for using the whole tumor lysateas a vaccine in order
totargettheseabnormalendothelialcells.Maybesomeofthe
success seen, when the tumor cell lysate was fed to the DC
was due to immune responses directed towards the glioma’s
vasculature. This open question is an important issue that
will be needed to be answered before the next major advance
towards cancer immunotherapy is made by using cell-based
materials.
4.4. Peptides
4.4.1. Peptides Vaccines. A more reﬁned approach is to use
possible antigenic peptides as the starting vaccine. One
knows exactly how much antigen is given to the DC, as
opposed to cells or tumor lysates. Liau and her coworkers
[153, 154] and Yu and his colleagues [155] used this strategy
to pulse their dendritic cells. Here tumors or tumor cell lines
w e r ea c i de l u t e da n dt h ee x t r a c t e dp e p t i d e sw e r el o a d e do n t o
the patient’s DC. Some T cells stimulated with this method
did generate T cells that inﬁltrated the recurrent glioma.
Liau et al. [153] did use peptides derived from allogeneic
glioma cell lines and then pulsed the patient’s DC with these
peptides. Little evidence of beneﬁcial antitumor immunity
was seen. This might explain why these DC researchers
quickly switched to using the tumor cell lysates obtained
from surgical specimens as the starting vaccine material.
The Duke group is using synthetic peptides-based strate-
gies to vaccinate EGFRvIII mutated GBM [156, 157]. The
University of Pittsburgh (Pittsburgh, PA) is using glioma
associated peptides (Survivin 96–104(2M), WT1 126–
134(1Y), EphA2 883–891, and IL-13Rα2 345–353(1A9V))
along with poly ICLC to vaccinate their patients [158]. One
of the advantages of using synthetic peptides, is that one
can design peptides that have a higher binding aﬃnities for
the MHC molecules than the actual tumor-derived peptides.
This is evidenced by the use of redesigned survivin, WT-1
and IL-13Rα2 peptides that the Pittsburgh group is using.12 Clinical and Developmental Immunology
Currently, the NYU Pediatric Neuro-Oncology Group in
collaboration with their Melanoma-DC program is treating
patients with the autologous pediatric DC with several
peptides (gp100, TRP2, EphA2 and her-2) for various pedi-
atric brain cancers (low grade gliomas, GBM, ependymoma,
and medulloblastoma). To date, they have vaccinated four
children without any signs of toxicity (Dr. Sharon Gardner,
personal communication). Since children survive longer
with brain cancers that their adult counterparts (CBTRUS,
2010), it will take some more time before the actuarial
data is collected before we know whether this therapy
worked.
Of course, one restriction using speciﬁc peptides is that
these patients have to be HLA-matched to assure that the
peptides will properly bind to the patient’s own MHC.
Roughly, half of population in the USA have the HLA-A2
allele, while Japan and China have higher proportions of
HLA-A24 allele, so most studies will need to be based on
their correct HLA-alleles. It remains to be seen whether
betterclinicalresponseswillbegeneratedwiththesepeptide-
based vaccines when compared to the cell lysate pulsed DC.
One possibility is to use the entire tumor-associated antigen
precursor protein as opposed to small peptides to pulse the
DC. Here the DC will process the proteins so that the correct
peptides will bind to its own unique MHC molecules. So
the patient’s own DC will customize their proper antigenic
peptides to ﬁt with their own immunogenetics.
4.5. Nongenetic Manipulated Vaccines. Cells can die by at
least three distinct pathways: apoptosis, autophagy, necro-
sis/paraptosis. Bredesen et al. [159] and Hotchkiss et al.
[160]havereviewedthebiologicalprocessesinvolvedinthese
diﬀerent pathways possess. Each pathway has its own unique
ability to interact with the immune system. These types of
vaccines could be used either with cell lines or the stem cells.
4.5.1. Apoptosis. Radiation and most chemotherapeutic
agents kill tumor cells by initiation of apoptosis [161, 162].
In response to these treatments, many in situ tumors initially
shrink and regress, only to reoccur with a more malignant
p h e n o t y p es o m e t i m el a t e r .D e s p i t eam a s s i v er e l e a s eo f
tumor-speciﬁcmaterial,includingtumorantigens,nolasting
immunity or tolerance occurs [163, 164]. Apoptosis has
been called the “silent death” and does not usually provoke
immunological responses. Most apoptotic cell remnants are
taken up by adjacent cells. Apoptosis is the driving pathway
that induces immune tolerance towards many self-antigens
either in the thymus for T cells or in the bone marrow
for B cells. The only way to override this immunotolerizing
property of apoptotic cells is use some immunostimulatory
cytokines like either IL-4 or GM-CSF [165, 166]o rb y
costimulatory molecules which help stimulate the APC
function [134].
4.5.2. Autophagy. This process occurs when cells are stressed
or deprived of key nutrients. These aﬀected cells undergo
a process whereby they begin to self-digest themselves. The
key morphological change in autophagic cells is having
double membraned vesicles within the cell. Like apoptotic
cells, autophagic cells do not induce in vivo inﬂammatory
responses. Autophagy may be a way that cells infected with
intracellular pathogens commit suicide, thereby limiting the
intracellular infection. Breast cancer cells treated with 4-
hydroxytamoxifen can be stimulated to undergo autophagy.
So autophagy may be useful for certain clinical therapies.
Howeversomebreastcellssurvivethistherapyandthenshow
drug resistance [167]. Under in vitro conditions, autophagic
tumor cells can be fed to dendritic cells and produce T-
eﬀector cells [168, 169].
4.5.3. Necrosis/Paraptosis. The mechanism of necrosis-
induction is the least well-deﬁned pathways of the three
forms of programmed cell death. It is thought that para-
ptosis is the programmed pathway that leads to necrosis.
Paraptoticcellsarecharacterizedbyaswellingandvacuoliza-
tion process that starts with the physical enlargement of
the endoplasmic reticulum (ER) and mitochondria [170].
Swollen cells suggested that ionic disregulation is accom-
panied by water inﬂux and retention. The disruption of
intracellular ion homeostasis ultimately causes these cells
to osmotically lyse releasing intracellular contents, such as
high gel mobility binding protein-1 (HMGB1) [171], heat
shock proteins [172], and various proteases. These proteins
act as “Danger Signals” promoting massive inﬂammation
and cellular immunity [173]. Hence, the best way to
improve the natural immunogenicity of the tumor cell is
by using necrotic/paraptotic cells. In contrast, vaccination
with necrotic tumor cells produces superior T-cell immune
responses in comparison to those responses elicited by
immunization with apoptotic cells [163, 164, 174]. The
advantages of using the tumor’s own natural death pathway
allows for the autologous glioma cells to be used as a vaccine
withouthavingtodoanygeneticmanipulations,whichcould
delay the time that a vaccine could be given to the patient
with a relapsing glioma.
Over the last decade our lab pioneered the use of
geneticallyengineered tumorcellswith membraneM-CSFas
a tumor vaccine (mM-CSF, 38–41). Activated macrophages
killed these mM-CSF transduced tumor cells quite easily in
at least four diﬀerent tumor models (rat glioma, human
glioma, mouse hepatoma [175], and rat breast cancer [176]).
In our glioma models (rat T9 and human U251), the mM-
CSF+ tumor cells are killed upon binding by the responding
monocytes followed by the release of reactive oxygen species
(ROS). The interaction with ROS resulted in paraptosis
[49, 177–179].
The limitation of using mM-CSF-based glioma vaccines
was that this tumor vaccine required living cells in order to
produce the immunogenic stimuli needed for the vaccine.
If the mM-CSF transduced T9 cells were either x-irradiated,
mitomycin-C or freeze-thawed prior to subcutaneous injec-
tion, the vaccinating eﬀects of mM-CSF+ glioma cells would
be lost [40]. Hence no IRB or study section would permit
a living tumor cell vaccine to be used in human patients.
So the mechanism by which these paraptotic cells were
induced, was investigated. This would then reproduce theClinical and Developmental Immunology 13
same immunogenicity of mM-CSF+ cells but now with
killed glioma cells. By forcing open BK (big potassium ion
channels) with phloretin or pimaric acid, paraptosis was
induced within the glioma cells along with the increased
production of heat shock proteins (HSP60, HSP70, HSP90,
and Grp94) and the peripheral migration of HMGB1 to the
cell surface. When these cells now osmotically lyse, all these
“danger signals” are now released and available to stimulate
the local APCs. All vaccinating eﬀects of living mM-CSF+
tumor cells can now be reproduced by using our killed
BK channel activated/killed glioma cells. All gliomas (rat
or human) that we tested have been successfully killed by
prolonged exposure to BK channel activators [175, 176]. So
this method can be developed for possible clinical trials.
5. Summary
Progress towards brain cancers by using immunotherapy
is slowly moving forward. Initial attempts used nonspe-
ciﬁc approaches like adjuvants and LAK cells. Nonspe-
ciﬁc cellular approaches were only eﬀective for a small
minority of fortunate people. The general focus now is
directed towards speciﬁc methods. These speciﬁc humoral
methods include using monoclonal antibodies and scFV
fragmented antibodies. Speciﬁc cellular approaches include
using TILs/CTLs, alloreactive CTL stimulated by MLRs,
all appear to have generated some clinical success. Active
immunization with autologous DCs that have been loaded
with tumor-antigens also appear to generate long-term
survivors. Glioma cells seem to possess numerous tumor-
associated antigens. Identiﬁcation of other strategies that can
be combined with immunotherapy approaches will certainly
improve our success against these lethal brain cancers. We
look forward towards the next chapter of this story as the
ﬁeld continues to mature.
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